Audio replay of the June 30 2021 Combined Shareholders’ Meeting
Replay of the audio transcript in the audio player below: https://www.ab-science.com/wp-content/uploads/2021/07/2021-07-01_AG_AB_Science_du_30_Juin_2021.mp3
Webcast presentation following the voluntary hold of clinical studies with masitinib
08/06/2021 : Presentation of the webcast that was held following the voluntary hold of clinical studies with masitinib
Masitinib in Prostate Cancer Webcast Presentation
25/05/2021 – Presentation of the webcast held on May 25, 2021 on masitinib in prostate Cancer Download PDF
Boursorama interview of Alain Moussy, CEO of AB Science
23/12/2020 – Read the interview of Alain Moussy, CEO of AB Science, in Boursorama
Equity financing for a maximum of 4 million shares with Alpha Blue Ocean’s PACT
16/11/2020 – AB Science secures equity financing for a maximum of 4 million shares with Alpha Blue Ocean’s PACT
Financing of 4.5 million euros through the issuance of bonds convertible into new ordinary shares
29/10/2020 – AB Science announces a financing of 4.5 million euros through the issuance of bonds convertible into new ordinary shares
Positive top-line Phase 3 results for oral masitinib in severe asthma
20/10/2020 – AB Science announces positive top-line Phase 3 results for oral masitinib in severe asthma
Results from masitinib study AB07015 in severe asthma selected for presentation at an American Thoracic Society symposium
13/10/2020 – Results from masitinib study AB07015 in severe asthma selected for presentation at an American Thoracic Society (ATS) symposium held on October 16, 2020
First half of 2020 results
30/09/2020 – AB Science reports its revenues for the first half of 2020
AB Science Presents Phase 2B/3 Study Results in Progressive Multiple Sclerosis at the World’s Largest Multiple Sclerosis Research Conference
14/09/2020 – AB Science presents Phase 2B/3 study results in Progressive Multiple Sclerosis at the world’s largest Multiple Sclerosis research conference